Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
نویسندگان
چکیده
منابع مشابه
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.
Botulinum neurotoxin has revolutionized the treatment of spasticity and is now administered worldwide. There are currently three leading botulinum neurotoxin type A products available in the Western Hemisphere: onabotulinum toxin-A (ONA) Botox(®), abobotulinum toxin-A (ABO), Dysport(®), and incobotulinum toxin A (INCO, Xeomin(®)). Although the efficacies are similar, there is an intense debate ...
متن کاملBotulinum Toxins (BOTOX, DYSPORT, MYOBLOC and XEOMIN) - 10/13
Botulinum is a family of toxins produced by the anaerobic organism Clostridia botulinum. There are seven distinct serotypes designated as type A, B, C-1, D, E, F, and G. In the United States, four preparations of botulinum are commercially available, three using type A serotype and one using type B. The three formulations of botulinum toxin type A are onabotulinumtoxinA (BOTOX), abobotulinumtox...
متن کاملBotox and Dysport: is there a dose conversion ratio in dermatology and aesthetic medicine?
To the Editor: The use of botulinum neurotoxin A is the most frequent intervention in aesthetic medicine. Sales of the two main preparations—Botox (Allergan Inc, Irvine, CA) and Dysport (Ipsen Ltd, Slough, Berkshire, UK)—amounted to USD $1 billion in 2007, and the trend is still growing. Even after 15 years of clinical use, the unit equivalence between these two main botulinum neurotoxin A prod...
متن کاملContent of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®
BACKGROUND Botulinum neurotoxin type A (BoNT/A) is the active substance in preparations used for the highly effective treatment of neurologic disorders such as cervical dystonia, blepharospasm, or spasticity, as well as other indications such as axillary and palmar hyperhidrosis, and urologic disorders. OBJECTIVE To determine the amount of BoNT/A protein present in pharmaceutical preparations...
متن کاملOnabotulinumtoxinA (Botox®) and AbobotulinumtoxinA (Dysport®) Esansiyel Blefarospazm Tedavisinde Botox® ve Dysport® un Uzun Dönem Sonuçları
Objective:To compare the clinical characteristics and outcomes of patients with blepharospasm who were treated with OnabotulinumtoxinA (Botox®) and AbobotulinumtoxinA (Dysport®). Methods: A total of 100 eyes of 78 patients who were diagnosed with blepharospasm were evaluated during a retrospective, randomized, parallel group study. The severity of spasm, eyelid closing force, and functional vis...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Toxins
سال: 2016
ISSN: 2072-6651
DOI: 10.3390/toxins8030065